Tralokinumab is effective and safe for the treatment of patients with moderate to severe AD through 6 total years of treatment.

A new vaccine from companies Pfizer and Valneva meant to prevent Lyme disease may be one step closer to approval.

The FDA accepts a New Drug Application for bezuclastinib to treat nonadvanced systemic mastocytosis based on positive data from the SUMMIT trial.

Patients with dermatomyositis in the US experience substantial variability in treatment, high glucocorticoid exposure, and significant healthcare utilization.

Acne is a common and clinically relevant adverse event among patients with IBD receiving JAK inhibitors. Acne occurs in 8.6% of individuals with inflammatory bowel diseases (IBD) who are receiving ...